PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Nano Bridging Molecules S.A

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Nano Bridging Molecules SA Announces Successful Conclusion of its Second Round Financing - Nano Bridging Molecules S.A (NBM), a Swiss early stage med-tech company devoted to developing new generation medical implant surface modifications, announced the successful conclusion of the second of three planned financing rounds
Nano Bridging Molecules SA Announces Successful Conclusion of its Second Round Financing

 

NewswireToday - /newswire/ - Gland, Switzerland, 2009/08/17 - Nano Bridging Molecules S.A (NBM), a Swiss early stage med-tech company devoted to developing new generation medical implant surface modifications, announced the successful conclusion of the second of three planned financing rounds.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Following oversubscription of the company’s first funding round in 2007 NBM significantly expanded its pre-clinical testing program, embarked on its first dental human clinical trial, recruited key scientific and clinical research staff and relocated its operations to purpose built laboratories and new offices in the Swiss canton of Vaud. Notwithstanding the current economic downturn the company has fully subscribed its second funding round. The funds raised are being used to conclude a 52 week large animal pre-clinical study (one of the largest of its kind conducted in Switzerland), commencement of orthopedic pre-clinical studies and expansion of its ongoing human dental clinical trials with the establishment of additional study centers in each of Europe and the US. The company is working closely with regulatory consultants aiming to have its first CE Marked dental implant surface treatment on the market in Q4 2010 and to achieve first sales in the orthopedics area in 2012.

About Nano Bridging Molecules S.A.

NBM (nbmolecules.com) is an award winning company which owns the global rights to develop, manufacture and market its SurfLink® technology. At the heart of this technology are patented multi-phosphonated molecules which have been developed over a twelve year period by world-leading, multi-disciplinary scientific teams from the University of Geneva and Ecole Polytechnique Fédérale de Lausanne.

Presently patients requiring joint replacement or spinal implant surgery are required to wait for as long as they possibly can before being operated on as a direct consequence of the limited life span of today’s devices and the likelihood they will, at some point, need to be replaced. Covalently bound to implant surfaces prior to surgery, NBM’s SurfLink® molecules facilitate a chemical reaction that naturally fuses treated implant surfaces to the patient’s bone. This gives rise to the exciting prospect of patients, regardless of age, being able to receive SurfLink® treated implants which will provide truly long term if not a lifetime of service.

For more information please contact:
Björn-Owe Aronsson, a founder and CTO for scientific or technical information
T: +41 (0) 22 354 0054 - E: bjorn-owe.aronsson[.]nbmolecules.com.

Neville Drower, CAO and General Counsel in respect of commercial, regulatory or legal matters
T: +41 (0) 22 354 0051 - E: neville.drower[.]nbmolecules.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Nano Bridging Molecules S.A

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Nano Bridging Molecules SA Announces Successful Conclusion of its Second Round Financing

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Neville Drower - NBMolecules.com 
+41 22-354-0054 neville.drower[.]nbmolecules.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Nano Bridging Molecules S.A securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Nano Bridging Molecules S.A / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)